Literature DB >> 7674315

Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives.

G Marra1, C R Boland.   

Abstract

Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominant disorder characterized by the occurrence within a family of multiple cases of colorectal cancer in the absence of gastrointestinal polyposis. The prevalence of this syndrome is not yet clear, but it may account for 1%-5% of all colorectal cancers. Prior to the identification of the genetic basis of this syndrome, the disease was recognized by the familial aggregation of colorectal cancers that had an early age of onset, an excess of proximally located, and often multiple, primary tumors, and an excess occurrence of cancers in certain other organs. The recent description of an abnormality called "microsatellite instability," present in almost all cancers from HNPCC patients and in about 12%-15% of sporadic cases, led to a series of discoveries that linked this type of genomic instability to a defect in the DNA mismatch repair (MMR) system. Independent investigators have identified four HNPCC genes: hMSH2 (a homologue of the prokaryotic DNA MMR gene MutS) and hMLH1, hPMS1, and hPMS2 (all homologues of the prokaryotic DNA MMR gene MutL). Mutations in each of the four genes have been found in the germline cells of HNPCC families. A major target for research in this area is the development of clinically practical screening tests for the genetic carrier state of HNPCC.

Entities:  

Mesh:

Year:  1995        PMID: 7674315     DOI: 10.1093/jnci/87.15.1114

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  100 in total

1.  Two common forms of the human MLH1 gene may be associated with functional differences.

Authors:  P Hutter; A Couturier; C Rey-Berthod
Journal:  J Med Genet       Date:  2000-10       Impact factor: 6.318

2.  Detection of microsatellite instability by fluorescence multiplex polymerase chain reaction.

Authors:  K D Berg; C L Glaser; R E Thompson; S R Hamilton; C A Griffin; J R Eshleman
Journal:  J Mol Diagn       Date:  2000-02       Impact factor: 5.568

Review 3.  Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes.

Authors:  Marina Pajic; Christopher J Scarlett; David K Chang; Robert L Sutherland; Andrew V Biankin
Journal:  Hum Genet       Date:  2011-04-23       Impact factor: 4.132

Review 4.  Apoptosis and colorectal cancer.

Authors:  A J M Watson
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

5.  A study on mutational dynamics of simple sequence repeats in relation to mismatch repair system in prokaryotic genomes.

Authors:  Pankaj Kumar; H A Nagarajaram
Journal:  J Mol Evol       Date:  2012-03-14       Impact factor: 2.395

Review 6.  Lower gastrointestinal tract cancer predisposition syndromes.

Authors:  Neel B Shah; Noralane M Lindor
Journal:  Hematol Oncol Clin North Am       Date:  2010-12       Impact factor: 3.722

7.  MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study.

Authors:  Mireia Gausachs; Pilar Mur; Julieta Corral; Marta Pineda; Sara González; Llúcia Benito; Mireia Menéndez; Josep Alfons Espinàs; Joan Brunet; María Dolores Iniesta; Stephen B Gruber; Conxi Lázaro; Ignacio Blanco; Gabriel Capellá
Journal:  Eur J Hum Genet       Date:  2012-01-25       Impact factor: 4.246

8.  Phosphorylated hMSH6: DNA mismatch versus DNA damage recognition.

Authors:  Saravanan Kaliyaperumal; Steve M Patrick; Kandace J Williams
Journal:  Mutat Res       Date:  2010-10-28       Impact factor: 2.433

Review 9.  Molecular basis for subdividing hereditary colon cancer?

Authors:  W M Grady
Journal:  Gut       Date:  2005-12       Impact factor: 23.059

10.  Clinical characteristics and diagnosis of patients with hereditary nonpolyposis colorectal cancer.

Authors:  San-Jun Cai; Ye Xu; Guo-Xiang Cai; Peng Lian; Zu-Qing Guan; Shan-Jing Mo; Meng-Hong Sun; Qi Cai; Da-Ren Shi
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.